PainIn Clinical Trials

ARA-290

Subcutaneous injection, Intravenous

Overview

A synthetic 11-amino acid peptide derived from the structure of erythropoietin (EPO) that selectively activates the innate repair receptor (IRR), a heteromer of the EPO receptor and the beta common receptor (CD131). Unlike EPO, ARA-290 does not stimulate erythropoiesis or promote thrombosis.

Mechanism of Action

It produces cytoprotective, anti-inflammatory, and tissue-reparative effects by activating the IRR on neurons, immune cells, and endothelial cells..

Research Summary & Key Findings

Phase 2 trials in patients with sarcoidosis-related small fiber neuropathy showed significant improvement in corneal nerve fiber density and reduction in neuropathic pain (Dahan et al., Mol Med, 2013). Preclinical studies demonstrated neuroprotective effects in diabetic neuropathy and cardiac ischemia-reperfusion injury. The selective IRR activation without erythropoietic effects avoids the thrombotic risks that limited EPO-based neuroprotection strategies.

Clinical Status

In Clinical Trials

ARA-290 is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.

Administration Routes

Subcutaneous injectionIntravenous

Related Peptides in Pain

Find a Provider

Find a verified provider who offers ARA-290 therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply ARA-290.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.